Thus, it is reasonable to suggest that promoter hypermethylation of HOXA4 gene could be an epigenetic mechanism mediating IM resistance in CML patients. The gene discussed is HOXA4; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.